Anthrax Vaccines Industry Research Report 2024

Anthrax Vaccines Industry Research Report 2024


Summary

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
According to APO Research, the global Anthrax Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Anthrax Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Anthrax Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Anthrax Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Anthrax Vaccines include Emergent BioSolutions, Merial, Merck, Zoetis, Bayer Sanidad Animal, Colorado Serum, PharmAthene, Tiankang and Biogénesis-Bago, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anthrax Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anthrax Vaccines.
The report will help the Anthrax Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Anthrax Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anthrax Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
Biogénesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Santé Animale
Intervac
JOVAC
Anthrax Vaccines segment by Type

Live Vaccines
Cell free PA Vaccines
Anthrax Vaccines segment by Application

Human Use
Animal Use
Anthrax Vaccines Segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthrax Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anthrax Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthrax Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anthrax Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anthrax Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Anthrax Vaccines Market Size (2019-2030) & (US$ Million)
2.2.2 Global Anthrax Vaccines Sales (2019-2030)
2.2.3 Global Anthrax Vaccines Market Average Price (2019-2030)
2.3 Anthrax Vaccines by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 Live Vaccines
2.3.3 Cell free PA Vaccines
2.4 Anthrax Vaccines by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Human Use
2.4.3 Animal Use
3 Market Competitive Landscape by Manufacturers
3.1 Global Anthrax Vaccines Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Anthrax Vaccines Sales (M Doses) of Manufacturers (2019-2024)
3.3 Global Anthrax Vaccines Revenue of Manufacturers (2019-2024)
3.4 Global Anthrax Vaccines Average Price by Manufacturers (2019-2024)
3.5 Global Anthrax Vaccines Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Anthrax Vaccines, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Anthrax Vaccines, Product Type & Application
3.8 Global Manufacturers of Anthrax Vaccines, Date of Enter into This Industry
3.9 Global Anthrax Vaccines Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Emergent BioSolutions
4.1.1 Emergent BioSolutions Company Information
4.1.2 Emergent BioSolutions Business Overview
4.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
4.1.5 Emergent BioSolutions Recent Developments
4.2 Merial
4.2.1 Merial Company Information
4.2.2 Merial Business Overview
4.2.3 Merial Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Merial Anthrax Vaccines Product Portfolio
4.2.5 Merial Recent Developments
4.3 Merck
4.3.1 Merck Company Information
4.3.2 Merck Business Overview
4.3.3 Merck Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Merck Anthrax Vaccines Product Portfolio
4.3.5 Merck Recent Developments
4.4 Zoetis
4.4.1 Zoetis Company Information
4.4.2 Zoetis Business Overview
4.4.3 Zoetis Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Zoetis Anthrax Vaccines Product Portfolio
4.4.5 Zoetis Recent Developments
4.5 Bayer Sanidad Animal
4.5.1 Bayer Sanidad Animal Company Information
4.5.2 Bayer Sanidad Animal Business Overview
4.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
4.5.5 Bayer Sanidad Animal Recent Developments
4.6 Colorado Serum
4.6.1 Colorado Serum Company Information
4.6.2 Colorado Serum Business Overview
4.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
4.6.5 Colorado Serum Recent Developments
4.7 PharmAthene
4.7.1 PharmAthene Company Information
4.7.2 PharmAthene Business Overview
4.7.3 PharmAthene Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.7.4 PharmAthene Anthrax Vaccines Product Portfolio
4.7.5 PharmAthene Recent Developments
4.8 Tiankang
4.8.1 Tiankang Company Information
4.8.2 Tiankang Business Overview
4.8.3 Tiankang Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Tiankang Anthrax Vaccines Product Portfolio
4.8.5 Tiankang Recent Developments
4.9 Biogénesis-Bago
4.9.1 Biogénesis-Bago Company Information
4.9.2 Biogénesis-Bago Business Overview
4.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
4.9.5 Biogénesis-Bago Recent Developments
4.10 CAVAC
4.10.1 CAVAC Company Information
4.10.2 CAVAC Business Overview
4.10.3 CAVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.10.4 CAVAC Anthrax Vaccines Product Portfolio
4.10.5 CAVAC Recent Developments
4.11 Rosenbusch
4.11.1 Rosenbusch Company Information
4.11.2 Rosenbusch Business Overview
4.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
4.11.5 Rosenbusch Recent Developments
4.12 Agrovet
4.12.1 Agrovet Company Information
4.12.2 Agrovet Business Overview
4.12.3 Agrovet Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.12.4 Agrovet Anthrax Vaccines Product Portfolio
4.12.5 Agrovet Recent Developments
4.13 Vecol
4.13.1 Vecol Company Information
4.13.2 Vecol Business Overview
4.13.3 Vecol Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.13.4 Vecol Anthrax Vaccines Product Portfolio
4.13.5 Vecol Recent Developments
4.14 CVCRI
4.14.1 CVCRI Company Information
4.14.2 CVCRI Business Overview
4.14.3 CVCRI Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.14.4 CVCRI Anthrax Vaccines Product Portfolio
4.14.5 CVCRI Recent Developments
4.15 IVPM
4.15.1 IVPM Company Information
4.15.2 IVPM Business Overview
4.15.3 IVPM Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.15.4 IVPM Anthrax Vaccines Product Portfolio
4.15.5 IVPM Recent Developments
4.16 Prondil
4.16.1 Prondil Company Information
4.16.2 Prondil Business Overview
4.16.3 Prondil Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.16.4 Prondil Anthrax Vaccines Product Portfolio
4.16.5 Prondil Recent Developments
4.17 CDV
4.17.1 CDV Company Information
4.17.2 CDV Business Overview
4.17.3 CDV Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.17.4 CDV Anthrax Vaccines Product Portfolio
4.17.5 CDV Recent Developments
4.18 Indian Immunologicals
4.18.1 Indian Immunologicals Company Information
4.18.2 Indian Immunologicals Business Overview
4.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
4.18.5 Indian Immunologicals Recent Developments
4.19 Botswana Vaccine Institute
4.19.1 Botswana Vaccine Institute Company Information
4.19.2 Botswana Vaccine Institute Business Overview
4.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
4.19.5 Botswana Vaccine Institute Recent Developments
4.20 Ceva Santé Animale
4.20.1 Ceva Santé Animale Company Information
4.20.2 Ceva Santé Animale Business Overview
4.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
4.20.5 Ceva Santé Animale Recent Developments
4.21 Intervac
4.21.1 Intervac Company Information
4.21.2 Intervac Business Overview
4.21.3 Intervac Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.21.4 Intervac Anthrax Vaccines Product Portfolio
4.21.5 Intervac Recent Developments
4.22 JOVAC
4.22.1 JOVAC Company Information
4.22.2 JOVAC Business Overview
4.22.3 JOVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
4.22.4 JOVAC Anthrax Vaccines Product Portfolio
4.22.5 JOVAC Recent Developments
5 Global Anthrax Vaccines Market Scenario by Region
5.1 Global Anthrax Vaccines Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Anthrax Vaccines Sales by Region: 2019-2030
5.2.1 Global Anthrax Vaccines Sales by Region: 2019-2024
5.2.2 Global Anthrax Vaccines Sales by Region: 2025-2030
5.3 Global Anthrax Vaccines Revenue by Region: 2019-2030
5.3.1 Global Anthrax Vaccines Revenue by Region: 2019-2024
5.3.2 Global Anthrax Vaccines Revenue by Region: 2025-2030
5.4 North America Anthrax Vaccines Market Facts & Figures by Country
5.4.1 North America Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Anthrax Vaccines Sales by Country (2019-2030)
5.4.3 North America Anthrax Vaccines Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Anthrax Vaccines Market Facts & Figures by Country
5.5.1 Europe Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Anthrax Vaccines Sales by Country (2019-2030)
5.5.3 Europe Anthrax Vaccines Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Anthrax Vaccines Market Facts & Figures by Country
5.6.1 Asia Pacific Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Anthrax Vaccines Sales by Country (2019-2030)
5.6.3 Asia Pacific Anthrax Vaccines Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Anthrax Vaccines Market Facts & Figures by Country
5.7.1 Latin America Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Anthrax Vaccines Sales by Country (2019-2030)
5.7.3 Latin America Anthrax Vaccines Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Anthrax Vaccines Market Facts & Figures by Country
5.8.1 Middle East and Africa Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Anthrax Vaccines Sales by Country (2019-2030)
5.8.3 Middle East and Africa Anthrax Vaccines Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Anthrax Vaccines Sales by Type (2019-2030)
6.1.1 Global Anthrax Vaccines Sales by Type (2019-2030) & (M Doses)
6.1.2 Global Anthrax Vaccines Sales Market Share by Type (2019-2030)
6.2 Global Anthrax Vaccines Revenue by Type (2019-2030)
6.2.1 Global Anthrax Vaccines Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Anthrax Vaccines Revenue Market Share by Type (2019-2030)
6.3 Global Anthrax Vaccines Price by Type (2019-2030)
7 Segment by Application
7.1 Global Anthrax Vaccines Sales by Application (2019-2030)
7.1.1 Global Anthrax Vaccines Sales by Application (2019-2030) & (M Doses)
7.1.2 Global Anthrax Vaccines Sales Market Share by Application (2019-2030)
7.2 Global Anthrax Vaccines Revenue by Application (2019-2030)
7.2.1 Global Anthrax Vaccines Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Anthrax Vaccines Revenue Market Share by Application (2019-2030)
7.3 Global Anthrax Vaccines Price by Application (2019-2030)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Anthrax Vaccines Value Chain Analysis
8.1.1 Anthrax Vaccines Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Anthrax Vaccines Production Mode & Process
8.2 Anthrax Vaccines Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Anthrax Vaccines Distributors
8.2.3 Anthrax Vaccines Customers
9 Global Anthrax Vaccines Analyzing Market Dynamics
9.1 Anthrax Vaccines Industry Trends
9.2 Anthrax Vaccines Industry Drivers
9.3 Anthrax Vaccines Industry Opportunities and Challenges
9.4 Anthrax Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings